Format

Send to

Choose Destination
Int J Mol Sci. 2010 Sep 2;11(9):3106-21. doi: 10.3390/ijms11093106.

Identification of tetranectin as a potential biomarker for metastatic oral cancer.

Author information

1
School of Dentistry and Dental Research Institute, University of California Los Angeles, Los Angeles, CA, USA; E-Mails: martha_eliz6@yahoo.com (M.E.A.-G.); liuliuxj@ucla.edu (X.L.).

Abstract

Lymph node involvement is the most important predictor of survival rates in patients with oral squamous cell carcinoma (OSCC). A biomarker that can indicate lymph node metastasis would be valuable to classify patients with OSCC for optimal treatment. In this study, we have performed a serum proteomic analysis of OSCC using 2-D gel electrophoresis and liquid chromatography/tandem mass spectrometry. One of the down-regulated proteins in OSCC was identified as tetranectin, which is a protein encoded by the CLEC3B gene (C-type lectin domain family 3, member B). We further tested the protein level in serum and saliva from patients with lymph-node metastatic and primary OSCC. Tetranectin was found significantly under-expressed in both serum and saliva of metastatic OSCC compared to primary OSCC. Our results suggest that serum or saliva tetranectin may serve as a potential biomarker for metastatic OSCC. Other candidate serum biomarkers for OSCC included superoxide dismutase, ficolin 2, CD-5 antigen-like protein, RalA binding protein 1, plasma retinol-binding protein and transthyretin. Their clinical utility for OSCC detection remains to be further tested in cancer patients.

KEYWORDS:

disease biomarker; oral squamous cell carcinoma; serum proteomics; tetranectin

PMID:
20957082
PMCID:
PMC2956083
DOI:
10.3390/ijms11093106
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center